Q-omics provides the consensus-scored CD14 profile across patient tissues and cancer cell-line models. CD14 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CD14 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CD14 protein abundance shows 25,787 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where CD14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD14 survival associations across molecular data types. CD14 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD14 RNA expression–survival associations across cancer types. High CD14 expression shows unfavorable associations in LUSC, UVM and LAML, but favorable associations in SKCM, LIHC and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CD14 RNA expression.
This table summarizes CD14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD14 shows lower tumor expression in LIHC, LUSC and COAD and higher tumor expression in KIRC, KIRP and THCA. The KIRC box plot shows higher CD14 RNA expression in tumor versus normal tissue (log2 FC = +1.990, t-test p < 0.001).
This table shows molecular features associated with CD14 in patient tissues and cancer cell lines. In patient samples, CD14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
